Asset Details
Do you wish to reserve the book?
CDK9 inhibitors in acute myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CDK9 inhibitors in acute myeloid leukemia
Do you wish to request the book?
CDK9 inhibitors in acute myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CDK9 inhibitors in acute myeloid leukemia
2018
Overview
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as
MCL-1
,
MYC
, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Animals
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Biomedical and Life Sciences
/ Complications and side effects
/ Cyclin-Dependent Kinase 9 - antagonists & inhibitors
/ Cyclin-Dependent Kinase 9 - genetics
/ Cyclin-Dependent Kinase 9 - metabolism
/ Drug Evaluation, Preclinical
/ Humans
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - metabolism
/ MCL-1
/ MYC
/ Oncology
/ P-TEFb
/ Positive transcription elongation factor b
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ Review
